iPSCt

iPSCt, or iPSC-derived T cells, refers to T lymphocytes generated from induced pluripotent stem cells. This approach uses iPSCs reprogrammed from adult cells to create a renewable, uniform source of T cells for research and therapeutic applications. iPSCt can be engineered to express a defined T cell receptor (TCR) or chimeric antigen receptor (CAR) and then differentiated into mature, antigen-specific T cells.

Generation and differentiation: iPSCs are produced by reprogramming somatic cells (such as skin or blood cells). These iPSCs are then guided to become hematopoietic progenitor cells and subsequently mature into T cells through thymus-like differentiation, often via Notch signaling in co-culture systems (e.g., OP9-Dll1/Dll4) or artificial thymic organoids. Genetic engineering at the iPSC stage allows insertion of CARs or TCRs before T cell maturation. These efforts aim to produce off-the-shelf T cells with controlled memory/effector profiles.

Applications: The primary focus is cancer immunotherapy, where CAR-iPSC-T cells or TCR-engineered iPSC-T cells may offer a scalable alternative to patient-derived CAR-T cells. Additional uses include infectious disease modeling, autoimmune disease research, and drug screening. Allogeneic applications may utilize gene editing to reduce graft-versus-host and alloreactivity.

Advantages and challenges: iPSCt offers scalable production, consistent cell products, and early integration of genetic modifications. Challenges include achieving complete thymic-like maturation and functional activity, ensuring genetic stability and safety (mitigating teratoma risk from residual iPSCs), and navigating complex manufacturing and regulatory requirements.

Status: Most iPSCt research remains in preclinical stages, with a few programs moving toward early-phase clinical testing in recent years. See also iPSCs.